X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
16 mai 2023 08h30 HE
|
X4 Pharmaceuticals
BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit people with rare diseases...
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
04 mai 2023 06h05 HE
|
X4 Pharmaceuticals
Company to host webinar event on May 16th presenting new clinical data from the4WHIM Phase 3 trial; oral presentation to follow on May 21st at the 2023Clinical Immunology Society (CIS) Annual Meeting ...
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
26 avr. 2023 08h01 HE
|
X4 Pharmaceuticals
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases...
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
12 avr. 2023 08h00 HE
|
X4 Pharmaceuticals
X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2023 16h05 HE
|
X4 Pharmaceuticals
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the...
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
21 mars 2023 06h05 HE
|
X4 Pharmaceuticals
Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early 2H 2023, and...
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
07 mars 2023 08h01 HE
|
X4 Pharmaceuticals
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mars 2023 16h05 HE
|
X4 Pharmaceuticals
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the...
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
12 déc. 2022 08h30 HE
|
X4 Pharmaceuticals
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an...
X4 Pharmaceuticals Prices $65.0 Million Public Offering
07 déc. 2022 08h43 HE
|
X4 Pharmaceuticals
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of...